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INTRODUCTION
Cerebral malaria (CM) is a life-
 threatening complication of Plasmodium
falciparum infection (1). Plasmodium
berghei ANKA (PbA) infection is an ex-
perimental model of CM (ECM) in mice
that exhibits several of the neurological
manifestations observed in human CM.
Studies in both humans and animals
have demonstrated that dysregulated in-
flammatory responses to infection and
their effects on vascular endothelium
play a central role in disease progression
and outcome (2).
Sphingosine 1-phosphate (S1P) is a sig-
naling sphingolipid that regulates sev-
eral cellular processes implicated in CM
pathology, including inflammation and
vascular endothelial homeostasis (3). S1P
is produced by the phosphorylation of
sphingosine by sphingosine kinases (4)
and inactivated by S1P phosphatases or
S1P lyase (S1PL) (5). S1P can act intracel-
lularly (6) or function in an autocrine or
paracrine manner as an extracellular lig-
and for cell surface S1P receptors follow-
ing release via ABC transporters (5). S1P
is one of the most abundant biologically
active lysophospholipids (4) and exerts
its cellular effects through five G-protein-
coupled receptors (SIP receptor 1
[S1P1]–5), differentially distributed and
expressed on various cell types (7,8).
The main sources of S1P in blood are
considered to be endothelium, platelets
and red blood cells (RBCs), which store
and protect S1P from degradation in
plasma (9,10). A concentration gradient
of S1P exists between plasma (11,12) and
interstitial fluids (13) which is thought to
be a major regulator of lymphocyte
egress and trafficking (14). S1P also pro-
motes T-cell egress from lymphoid or-
gans through binding of S1P to lympho-
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Cerebral malaria (CM) is associated with excessive inflammatory responses and endothelial activation. Sphingosine 1- phosphate
(S1P) is a signaling sphingolipid implicated in regulating vascular integrity, inflammation and T-cell migration. We hypothesized
that altered S1P signaling during malaria contributes to endothelial activation and inflammation, and show that plasma S1P lev-
els were decreased in Ugandan children with CM compared with children with uncomplicated malaria. Using the Plasmodium
berghei ANKA (PbA) model of experimental CM (ECM), we demonstrate that humanized S1P lyase (hS1PL)–/– mice with reduced
S1P lyase activity (resulting in increased bio-available S1P) had improved survival compared with wild-type littermates. Prophy-
lactic and therapeutic treatment of infected mice with compounds that modulate the S1P pathway and are in human trials for
other conditions (FTY720 or LX2931) significantly improved survival in ECM. FTY720 treatment improved vascular integrity as indi-
cated by reduced levels of soluble intercellular adhesion molecule (sICAM), increased angiopoietin 1 (Ang1) (regulator of en-
dothelial quiescence) levels, and decreased Evans blue dye leakage into brain parenchyma. Furthermore, treatment with
FTY720 decreased IFNγ levels in plasma as well as CD4+ and CD8+ T-cell infiltration into the brain. Finally, when administered dur-
ing infection in combination with artesunate, FTY720 treatment resulted in increased survival to ECM. These findings implicate dys-
regulation of the S1P pathway in the pathogenesis of human and murine CM and suggest a novel therapeutic strategy to im-
prove clinical outcome in severe malaria.
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cyte S1P receptors. However, at high
 concentrations, S1P downregulates S1P
receptors and promotes closing of en-
dothelial tight junctions, resulting in
lymphocyte retention (15).
A number of agents have been used to
modulate S1P receptor signaling directly
(16). LX2931 specifically inhibits S1PL
function, thereby reducing S1P degrada-
tion and increasing S1P bioavailability.
At high concentrations, FTY720 (fin-
golimod) also affects S1PL (17), but its
main target is S1P receptor 1 (S1P1) (18).
FTY720 administration has proved bene-
ficial in experimental disease models
(19–23), and recently in human clinical
trials of relapsing multiple sclerosis (24).
Both S1P and FTY720 result in S1P1
 internalization and recycling (25,26),
FTY720 being a more efficient inducer of
receptor degradation (27). This func-
tional antagonism of S1P receptors leads
to lymphocyte retention in lymphoid tis-
sues, thus reducing the number of acti-
vated lymphocytes available to enter
sites of inflammation, including the cen-
tral nervous system (CNS) (28).
Based on the above observations sug-
gesting a role for S1P in the regulation of
biological processes implicated in the
pathogenesis of CM, we hypothesized
that S1P signaling is affected during ma-
laria infection in a manner that impacts
host immune responses deleteriously.
Studying both clinical human malaria
and animal models, we implicate altered
S1P signaling in CM pathogenesis.
Through genetic and pharmacologic
strategies to modulate S1P-to-S1P recep-
tor interactions, we show improved dis-
ease outcome associated with preserved
endothelium integrity, reduced host in-
flammation and T-cell influx into the
brain. Improved survival also was ob-
served when FTY720 was administered
following infection in combination with
a subcurative dose of artesunate. These
data suggest that treatment approaches
to enhance S1P-mediated activity, such
as administration of FTY720, may have
potential clinical utility as adjunctive
therapeutic strategies for individuals
with malaria.
MATERIALS AND METHODS
Study Participants
Plasma samples were collected from
children aged 0.6 to 10.6 years living in
an area of holoendemic malaria trans-
mission in Kampala, Uganda. Samples
were derived from an observational
case- control clinical study at Mulago
Hospital in Kampala. Children were di-
agnosed with uncomplicated or cerebral
malaria according to the World Health
Organization (1). The study was ap-
proved by Mulago Hospital Research
Ethics Committee, Makerere University
Faculty of Medicine Research Ethics,
Uganda National Council on Science
and Technology and Toronto Academic
Health Sciences Network Research.
Written informed consent was obtained
from all participants and/or their
guardians.
Mice, Parasites and Drug Regimens
The mice with diminished S1PL activ-
ity (hS1PL–/– mice, provided by Lexicon
Pharmaceuticals, The Woodlands, TX,
USA), were on a mixed genetic back-
ground (129S5/ SvEvBrd and C57BL/6J)
(29). Wild-type littermates were used as
controls in these experiments since the
response to P. berghei infection is mouse-
strain specific. FTY720 and LX2931 ex-
periments were performed using 6- to 8-
wk-old female C57BL/6 WT animals
(Charles River, Sherbrooke, QC, Canada).
All animals were housed at the Univer-
sity of Toronto according to animal use
guidelines and euthanized using an
overdose of anesthetic (isofluorane). At
least five animals per group were used
for each experiment.
Animals were treated daily with either
FTY720 (0.3 mg/kg, Selleck) or LX2931
(100 mg/kg, Lexicon Pharmaceuticals
Inc.) 1 d prior to and 1, 3 or 5 d after in-
traperitoneal (i.p.) infection with 1 × 106
PbA parasites. The compounds were re-
constituted in sterile water and adminis-
tered by gavage. For artesunate (Sigma-
Aldrich, St. Louis, MO, USA) treatment,
mice received a single i.p. injection of
10 mg/ kg diluted in RPMI medium
(Gibco, Burlington, ON, Canada) 5 d
after malaria  infection.
Plasma Protein and Lipid
Measurements
Human S1P levels were measured in
plasma samples by EIA following the
manufacturers’ guidelines (Echelon, dis-
tributed by Cedarelane, Burlington, ON,
Canada).
For measuring murine circulating
plasma cytokine levels, blood was col-
lected from mice on days 5 and 6 after
infection (p.i.) from the saphenous vein
in heparinized tubes (Starstedt, Mon-
treal, QC, Canada) or by cardiac punc-
ture into heparin-coated syringes. Blood
was centrifuged (Sorvall, distributed by
ThermoScientific, Asheville, NC, USA;
16,060g for 10 min), and plasma was col-
lected and stored at –80°C. Plasma cy-
tokine levels for IFNγ and TNF were
measured using an inflammatory cy-
tokine CBA kit (BD Bioscience, Missis-
sauga, ON, Canada). Levels of Ang1 and
sICAM as well as TNF and IFNγ in unin-
fected, but treated, control mice, were
measured by EIA following the manufac-
turer’s instructions (R&D, distributed by
Cedarelane). EIAs are much more sensi-
tive than CBAs, hence the apparent high
levels of TNF in uninfected mice in Sup-
plementary Figure 2.
Brain Lymphocyte Isolation
Brains were perfused with PBS,
 isolated and incubated with DNase
(Worthington, distributed by Cedare-
lane) and collagenase (Worthington) for
40 min at room temperature. Cells ob-
tained were washed (2% FBS/PBS) and
lymphocytes isolated using a 33% Per-
coll gradient. Lymphocytes were
washed (2% FBS/PBS), treated with
RBC lysis buffer (Sigma) and counted.
All cells were stained for CD4 (RM4.5,
Ebioscience, San Diego CA, USA), CD8
(53-6.7, Biolegend, distributed by
Cedarelane), and CD3 (17A2, Ebio-
science) for 20 min, washed, fixed in 1%
formalin and run on an LSR II flow cy-
tometer. Data were analyzed using
FlowJo software.
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Evans Blue Staining
A solution of 1% Evans blue dye was
made using Evans Blue powder (Sigma-
Aldrich) and PBS. The solution was filter
sterilized and, on day 7 p.i., 100 μL was
injected intravenously (i.v.) (or i.p., as in
Supplementary Figure 3, which explains
the lighter staining) into mice and left to
circulate for 1 h. Mice were euthanized
and brains perfused with PBS. Brains
were removed and photographed. Repre-
sentative photographs were chosen
based on animals with the most similar
parasitemia.
Statistical Analyses
Statistical analyses were performed
using GraphPad Prism. All data which
involved more than one experiment
were normalized to the geometric mean
of the infected but untreated group of
each experiment. For analyses involving
two groups, Mann-Whitney tests (MW)
were performed on nonparametric data.
For analyses involving three or more
groups, analysis of variance (ANOVA)
followed by the Bonferroni post hoc test
(BPt) were performed on parametric
data. Kruskal- Wallis tests (KW) followed
by the Dunn multiple comparison
(DMC) were performed for nonparamet-
ric data. For survival statistics, the log-
rank test (LRt) and the Fisher exact test
(FEt) were used. For the logistic regres-
sion model involving S1P levels, hemo-
globin levels and platelet counts, the
SPSS program was used.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Plasma S1P Is Decreased in Children
with Cerebral Malaria
To examine the biological relevance of
S1P in human severe malaria, we first
investigated plasma S1P levels in Afri-
can children with CM compared with
those with uncomplicated malaria (UM)
(Figure 1A). Median plasma S1P levels
were decreased significantly in Ugandan
children with CM compared with chil-
dren with UM (P < 0.0001). As expected,
we observed differences in hemoglobin
and platelet levels between CM and UM
groups (Figure 1B, C). However, after
correcting for anemia and thrombocyto-
penia and in accordance with recent data
(30), the difference in S1P levels ob-
served remained a significant and inde-
pendent predictor (logistic regression
model, P = 0.02) of cerebral malaria rela-
tive to uncomplicated controls. The lo-
gistic regression model used fit the data
well (Hosmer-Lemeshow, P = 0.38) and
discriminated between cerebral and un-
complicated malaria (c-index = 0.963,
95% CI = 0.92–1.0).
Survival Is Improved in Mice with
Decreased S1PL Activity in PbA-
Induced ECM
Having established that S1P levels were
decreased in children with CM, we inves-
tigated a potential causal role for S1P in
CM pathogenesis by examining the out-
come of infection in mice with decreased
S1PL activity, resulting in increased tissue
and plasma S1P levels (29). We infected
humanized S1PL deficient mice (hS1PL–/–)
with PbA (Figure 2A, left panel). Survival
was improved significantly in hS1PL–/–
mice compared with wild-type litter-
mates (95% versus 35% survival; P <
0.0001) with no effect on parasite burden
(Figure 2A, right panel). Thus, in ECM, 
as with our clinical data, increased S1P
levels were associated with improved
outcome.
The 35% survival rate observed in
wild-type littermates differs from the 0%
survival rate observed with C57BL/6
mice used in all other experiments. Ani-
mals used in this experiment were of
mixed background (129S5/SvEvBrd and
C57BL/6J), and since P. berghei infection
is mouse-strain specific, we used the ap-
propriate control of wild-type littermates
in these experiments.
Treatment with Either FTY720 or LX2931
Improves Survival in ECM
We assessed the effect of modulating
S1P signaling in ECM by treating mice
with the S1P receptor modulator FTY720
(0.3 mg/kg/day by gavage), starting at
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Figure 1. Plasma S1P is decreased in children with cerebral malaria. (A) S1P is decreased
in children with cerebral malaria. Plasma S1P levels were assayed in Ugandan children
with malaria. S1P levels were significantly lower in children with cerebral malaria (CM, n =
29) versus uncomplicated malaria (UM, n = 27), P < 0.0001, MW. (B) Hemoglobin levels are
decreased in children with cerebral malaria. Hemoglobin levels were significantly lower in
children with cerebral malaria (CM, n = 29) versus uncomplicated malaria (UM, n = 27), 
P < 0.0001, MW. (C) Platelet counts are decreased in children with cerebral malaria.
Counts were measured in Ugandan children with malaria, and were shown to be signifi-
cantly lower in children with cerebral malaria (CM, n = 29) versus uncomplicated malaria
(UM, n = 27), P < 0.0001, MW.
various points during the course of infec-
tion (Figure 2B, C, left panels). Both pro-
phylactic (initiation of FTY720 1 d prior
to infection) and therapeutic (initiation of
FTY720 1 d p.i.) treatment with FTY720
significantly increased survival (P <
0.0001 and P < 0.05 respectively, Figure
2B, C). Therapeutic interventions with
FTY720 initiated later during the course
of infection (3–5 d) did not reach statisti-
cal significance (data not shown). Treat-
ment with LX2931 (100 mg/ kg/day by
gavage) had a beneficial but less marked
effect on outcome than FTY720 (Supple-
mentary Figure 1). Prophylactic treat-
ment with LX2931 1 d prior to infection
did not lead to increased survival but
did provide a significant delay in the
onset of symptoms (P < 0.0001; Supple-
mentary Figure 1A). However, therapeu-
tic treatment during infection showed no
significant benefit (Supplementary Fig-
ure 1C).
Parasite burdens were not significantly
different between untreated and drug-
treated animals over the course of infec-
tion (Figure 2, right panels; Supplemen-
tary Figure 1B, D). The effects of both
compounds on survival therefore were at-
tributed to host response modulation
rather than anti-parasitic effects (although
an impact of drug treatment on parasite
viability and/or infectiousness was not
assessed directly and could have con-
tributed to the differences observed). We
next examined the effect of FTY720 on the
blood-brain barrier (BBB), which is dis-
rupted severely in cerebral malaria (31).
Treatment of ECM with FTY720
Decreases Endothelium Activation
and Enhances Blood-Brain Barrier
Integrity
S1P has been shown previously to limit
the effects of inflammatory mediators on
endothelium (32). Secretion of S1P by en-
dothelial cells may be critical for the
maintenance of the plasma S1P gradient
and vascular barrier homeostasis.
Plasma sICAM-1, a marker of endothe-
lial activation (33), was decreased in
FTY720-treated mice compared with un-
treated mice (Figure 3A). Elevated levels
in infected but untreated mice were de-
creased significantly in all animals
treated with FTY720 (P < 0.0001). Con-
versely, plasma Ang1, a marker of en-
dothelium quiescence and stability, was
increased in mice treated with FTY720
prophylactically compared with un-
treated animals (P = 0.02, Figure 3B).
Mice treated with FTY720 but not in-
fected with malaria showed no change in
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Figure 2. Modulating S1P levels improves survival in mice with P. berghei ANKA-induced
ECM. (A) Survival (left panel) is improved, while parasite burden remains unchanged (right
panel), in mice with decreased S1PL activity in P. berghei ANKA-induced ECM. Survival of
hS1PL–/– mice infected with 1 × 106 parasites i.p. was compared to their wild-type litter-
mates. Decreased S1PL activity (resulting in increased bioavailable S1P) provided a signifi-
cant survival advantage compared with control animals (two pooled independent ex-
periments [IE], n = 10/group/IE, LRt, P < 0.0001). (B,C,D) Mice were infected with 1 × 106
parasites i.p., and treated daily by gavage with FTY720 (0.3 mg/kg). Treatment with FTY720
provided a significant survival advantage if administered (B) 1 d prior to (two pooled IE, 
n ≥ 10/group/IE, LRt, P < 0.0001), (C) 1 d p.i. (three pooled IE, n ≥ 10/group/IE, LRt, P < 0.05)
or (D) 5 d p.i. in combination with a single dose of artesunate administered on d 5 of in-
fection (five pooled IE, n ≥ 10/group/IE, FEt, P = 0.05). Parasite burden remain unchanged
between groups for all these experiments (right panels).
either their sICAM-1 or Ang1 levels com-
pared with uninfected, untreated con-
trols (Supplementary Figure 2A, B).
Studies observing Evans blue staining
of the brain demonstrated that FTY720
treatment improved BBB integrity in
ECM. These experiments (Figure 3C; Sup-
plementary Figure 3) demonstrate the de-
crease in endothelium vascular leak ap-
parent in 1-day–preinfection and
1-day–postinfection drug-treated animals
(blue-grey, similar to uninfected control
animals) compared with the untreated in-
fected mice and animals treated on day 3
p.i. (dark blue staining). Collectively,
these data indicate that FTY720 treatment
preserves BBB and endothelium integrity.
FTY720 Treatment of ECM Decreases
Plasma IFNγ
Both IFNγ and TNF have been impli-
cated in the pathogenesis of CM (34,35),
and S1P has also been shown to influ-
ence T-cell IFNγ production (28). FTY720
treatment did not affect TNF plasma lev-
els (measured on day 5 p.i., P > 0.05, Fig-
ure 4A). However, IFNγ plasma levels,
measured on day 6 p.i. (Figure 4B), were
decreased significantly with pretreat-
ment and treatment 3 d p.i. (P < 0.01 and
P < 0.05 respectively). This decrease was
not observed in mice treated with FTY720
but not infected with malaria compared to
uninfected, untreated controls (Supple-
mentary Figure 2D). Pretreatment with
LX2931 significantly  decreased IFNγ but
not TNF levels measured at 5 d p.i. (Sup-
plementary Figure 1).
FTY720 Treatment of ECM Decreases
Central Nervous System Lymphocyte
Numbers and Granzyme A mRNA
during PbA Malaria Infection
FTY720 administration causes tran-
sient sequestration of circulating lym-
phocytes in lymph nodes and a sus-
tained decrease of lymphocytes in the
blood and spleen (13,14,36–38). Consis-
tent with other studies (38), we observed
a marked reduction of lymphocytes in
the blood (data not shown). Importantly
in the context of ECM, FTY720 can cross
the BBB and be phosphorylated within
the CNS (24). Since S1P receptors are ex-
pressed on all cell types found within the
CNS (25), FTY720 can restrict immune
cell entry into the CNS (39) and could
contribute to reduced CM pathology by
limiting lymphocyte infiltration into the
brain (40), a process implicated in ECM
pathogenesis (41). We show that lympho-
cyte infiltration (both CD4+ and CD8+
cells) in the brain is decreased in mice
treated with FTY720 1 d before infection
and 1 d p.i. (Figure 5A, B, CD4+: P < 0.05
and P < 0.001, CD8+: P < 0.05 and P <
0.01 respectively), as is expression of
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Figure 3. Treatment of ECM with FTY720 de-
creases endothelium activation and im-
proves blood-brain barrier integrity. (A)
Plasma levels of sICAM-1, a marker of en-
dothelial activation, are decreased in
FTY720-treated animals (P < 0.001, KW): for
(FTY720 [–1], P < 0.001, FTY720 [+1] P < 0.05
and FTY720 [+3], P < 0.001; DMC, three
pooled IE, n ≥ 3/group/IE). (B) Plasma levels
of Ang1, a marker of endothelial integrity,
are increased in animals treated with
FTY720 prophylactically (P < 0.01, KW and
DMC, two pooled IE, n ≥ 3/group/IE) but not
in animals treated during infection. (C)
Brains stained with Evans blue were har-
vested on day 7 p.i. Brains displayed are
from animals with the following parasitemia:
Wild type: 12.7%; FTY720 (–1): 20.6%; FTY720
(+1): 17.8%; FTY720 (+3): 11.9%. Brains from
FTY720-treated animals show improved en-
dothelium integrity (less blue dye leakage
from the blood into brain parenchyma) as
compared with the wild-type animal (two
pooled IE, n ≥ 3/group/IE).
Figure 4. FTY720 treatment of ECM de-
creases plasma IFNγ and TNF. (A) TNF
plasma levels trended toward a de-
crease in the plasma of all animals
treated with FTY720 (P > 0.05, ANOVA,
three pooled IE, n ≥ 5/group/IE). (B) IFNγ
plasma levels were decreased in the
plasma of animals treated with FTY720
1 d before infection and 3 d p.i. (P < 0.01
and P < 0.5 respectively, KW and DMC,
three pooled IE, n ≥ 5/group/IE).
granzyme A (GZMA), an inflammatory
mediator released by activated T cells
(Figure 5C). Decreased GZMA levels
were observed in all FTY720-treated mice
compared with untreated mice, although
the differences achieved statistical signif-
icance for only the FTY720 (–1) and
FTY720 (+3) treatment groups (P < 0.05
and P < 0.01 respectively). Brains were
perfused prior to measuring lymphocyte
counts in order to ensure that only se-
questered and not circulating lympho-
cytes were included in our results.
Treatment with FTY720 in Combination
with an Anti-Malarial Improves
Survival in ECM
We assessed the impact of therapeutic
FTY720 treatment (0.3 mg/kg/day by
gavage), starting at day 5 during the
course of infection (Figure 2D, left
panel) when administered in combina-
tion with a subcurative dose of arte-
sunate (10 mg/kg) on day 5. The combi-
nation treatment resulted in a significant
increase in survival over artesunate ther-
apy alone (P = 0.05, FEt, experiment re-
peated five times with similar trend).
DISCUSSION
Our data implicate the S1P pathway in
the pathobiology of human and experi-
mental CM, and highlight the effects of
S1P on endothelial quiescence and infec-
tion-induced inflammation in this con-
text. S1P levels were decreased signifi-
cantly in Ugandan children with cerebral
malaria (Figure 1), in contrast to increased
proinflammatory markers associated with
severe and complicated disease (1). This is
of particular interest since it has been
shown recently (42) that neurocognitive
functions are impaired in sphingosine ki-
nase 1 (Sphk1)–/– animals (animals defi-
cient in sphingosine kinase 1); Sphk1–/–
mice have reduced plasma S1P (43). Chil-
dren with cerebral malaria have de-
creased plasma S1P levels (see Figure 1),
and also can display impaired neurocog-
nitive functions once they have recov-
ered from infection (44). The dysregula-
tion of the S1P pathway therefore may
contribute to this process.
Genetic approaches using hS1PL–/– mice,
demonstrated that S1P lyase deficiency
conferred almost complete protection to
PbA-induced ECM (Figure 2A). Treat-
ment with either of two compounds (for
example, LX2931 and FTY720) known to
alter S1P signaling result in  increased
survival from ECM (Figure 3B, C; Sup-
plementary Figure 1A). Interestingly,
while no animals survived infection after
prophylactic LX2931 treatment, despite a
significant delay in mortality, 50% of ani-
mals treated prophylactically with
FTY720 survived ECM (FEt, P = 0.0002
for FTY720 treatment versus P = 1 for
LX2931 treatment). These differences
may be attributable to the observation
that, unlike FTY720, LX2931 does not
cross the BBB.
In order to enhance S1P bioavailability,
FTY720 or LX2931 administration was
preferred to that of S1P itself since FTY720
has recently been FDA approved for use
in multiple sclerosis and a phase 2A study
has just been completed with promising
results using LX2931 to treat rheumatoid
arthritis. As such, these compounds, un-
like synthetic S1P, have safety profiles in
humans (24,45), which would make their
application as malaria adjunctive therapy
imminently testable, with possible accel-
erated translation to clinical populations.
During FTY720 and LX2931 treatment,
oral rather than intravenous administra-
tion was preferred since it has been
shown that lower blood lymphocyte
counts can be achieved using this route
(38). Dosing was based on the preestab-
lished range shown to reduce lympho-
cyte numbers in the blood (15). We did
perform experiments at a higher dose
(3 mg/kg/day) in an attempt to increase
survival in ECM, however, this higher
dose did not confer additional survival
benefit (data not shown).
The administration of FTY720 had a
significant impact on endothelial in-
tegrity (Figure 3). Prophylactic treatment
resulted in increased Ang1 levels, a bio-
marker of endothelial quiescence, which
may explain the enhanced survival pro-
vided by prophylactic FTY720 treatment
since in humans, decreased Ang1 levels
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Figure 5. FTY720 treatment of ECM de-
creases lymphocyte numbers and
granzyme A mRNA in the brain. (A) Rela-
tive CD8+ and (B) CD4+ T-cell numbers iso-
lated from the brains of mice infected for
6 d. Numbers were decreased in animals
treated with FTY720 1 d before infection
and 1 d p.i. (CD4+: P < 0.5 and P < 0.001,
CD8+: P < 0.5 and P < 0.01 respectively, KW
and DMC, two pooled IE, n ≥ 4/group/IE)
(C) GZMA mRNA levels were decreased in
the brains of FTY720-treated animals com-
pared with control animals: for (FTY720
[–1], P < 0.05, FTY720 [+1] P > 0.05 and
FTY720 [+3], P < 0.01; KW and DMC, two
pooled IE, n ≥ 3/group/IE).
are associated with CM (46). Increased
Ang1 and S1P levels have also been asso-
ciated with the maintenance of vascular
integrity (47,48).
S1P has been shown recently to induce
nitric oxide (NO) (49) as well as vascular
endothelial growth factor (VEGF) expres-
sion (50) in endothelial cells. Notably
both reduced NO and reduced VEGF
levels have been associated with severe
and cerebral malaria (51) and may be re-
lated to the decreased S1P levels we ob-
served in the cerebral malaria patients
(see Figure 1). Since increased bioavail-
able NO has been associated with resist-
ance to malaria (52), it also would be of
interest to determine whether S1P levels
correlate with clinical response and out-
come in human infection.
Decreases in inflammatory markers
have been associated with protection
from ECM (41), which suggests that re-
duced levels of IFNγ observed with
FTY720 and LX2931 treatment may have
contributed to increased survival (Fig-
ure 4; Supplemental Figure 1).
In addition to improving endothelial
integrity and inflammation, the adminis-
tration of FTY720 significantly reduced
the number of CD4+ and CD8+ lympho-
cytes migrating into the brain during
PbA infection (Figure 5C, D). However,
other types of lymphocytes which we
did not assess also may have been af-
fected by FTY720 treatment. Although
Th17 cells have not been implicated yet
in malaria, FTY720 has been shown to
 attenuate Th17 cell accumulation in a
model of neuritis (53) and in multiple
sclerosis patients (54). FTY720 also has
been shown to affect regulatory T cells
(Tregs) by increasing the expression of
IL-10 and CTLA-4 in vitro (55), promot-
ing Treg activity in vivo (56) and more re-
cently by modulating the reciprocal dif-
ferentiation of inducible Tregs and Th1
cells (57). The role of Tregs in malaria in-
fection remains controversial (58), and
therefore the impact of S1P on this cell
type during infection requires further
 investigation.
Despite FTY720 mainly affecting
T cells (15), an effect on B and NK cells
cannot be excluded (59). NK cells have
been implicated as potent IFNγ produc-
ers during malaria infection (60) and the
reduced inflammation observed in
FTY720-treated animals (Figure 4B) may
result partially from an effect of FTY720
on NK cells. Although it was thought
that myeloid cells were not affected sig-
nificantly by FTY720 treatment (61),
FTY720 has been shown to skew den-
dritic cell and macrophage responses to-
wards anti-inflammatory profiles (28). Fi-
nally, the effect of FTY720 on other cell
types in the CNS such as microglia
which have been implicated in the
pathogenesis of cerebral malaria (62) or
astrocytes which are integral to BBB
maintenance (63), and strongly express
S1P receptors (64), cannot be excluded.
A recent publication implicates the S1P
pathway in life-threatening infectious
disease processes (65). The authors re-
port that in an LPS model of sepsis in
mice, knockdown of Sphk1 through the
use of small interfering RNAs leads to
recovery, characterized by decreased cel-
lular infiltration and inflammation (65).
Sphk1 phosphorylates sphingosine, re-
sulting in S1P (4) and knocking down its
function might suggest reduced S1P
plasma levels (43). However, the authors
did not report on extracellular or plasma
S1P levels and suggest that the blockade
of Sphk1 does not affect the extracellular
S1P gradient required to maintain vascu-
lar barrier function (65). Our findings
whereby FTY720 treatment and de-
creased S1PL activity improves survival
to experimental cerebral malaria are
based on a dysregulation of the extracel-
lular S1P gradient. The apparent contra-
diction between our results therefore
could be explained by the regulation of
intracellular versus extracellular or
plasma S1P. Furthermore, differential tis-
sue and cell receptor subtype expression
also can contribute to different or oppos-
ing roles in maintaining vascular barrier
function, and may contribute to our ob-
served results in human and murine CM.
In summary, FTY720 treatment modu-
lated a number of pathways central to
the pathophysiology of ECM. FTY720 ad-
ministration improved vascular integrity
in the brain (increased Ang1 levels, re-
duced sICAM-1 levels and vascular
leak), as well as reduced inflammation
(IFNγ levels) and reduced T-cell infiltra-
tion in the brain (CD4+ and CD8+ cells).
Its administration in combination with a
subcurative dose of artesunate during in-
fection led to a biologically significant in-
crease in ECM survival.
A recent report has questioned the util-
ity of the experimental CM model, how-
ever this report has been challenged by
the research community with most inves-
tigators agreeing there are a number of
features shared between human (and es-
pecially pediatric CM) and murine CM
(66,67). Moreover, our approach obviates
this criticism by first establishing the bio-
logical relevance of the S1P pathway to
human disease by studying informative
patient populations before moving to an-
imal models to examine mechanism and
causality.
Using human clinical samples com-
bined with genetic approaches in
hS1PL–/– mice, as well as compounds
which modulate the S1P pathway, we
provide strong evidence implicating the
S1P pathway in malaria pathogenesis.
Considerable malaria research has fo-
cused on host protein rather than lipid
pathways, which we have shown can
play an important role in infection. The
S1P signaling cascade may represent a
novel target for adjunctive therapeutics
for severe and cerebral malaria. We have
observed a small increase in survival in
animals treated therapeutically with
FTY720 in combination with a subcura-
tive dose of anti-malarial (FEt, P = 0.05)
as compared to animals treated with the
antimalarial alone (Figure 2D, left panel).
Given that FTY720 (68) and LX2931 have
an established safety profile in human
trials (FTY720 has recently been ap-
proved by the FDA for use in the treat-
ment of multiple sclerosis), this hypothe-
sis could be directly tested.
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